Zio XT for detecting cardiac arrhythmias (MTG52)
Evidence-based recommendations on Zio XT for detecting cardiac arrhythmias
Search results
21 results
-
-
The PLASMA system for transurethral resection and haemostasis of the prostate (MTG53)
Evidence-based recommendations on the PLASMA system for transurethral resection and haemostasis of the prostate
-
Galcanezumab for preventing migraine (TA659)
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults
-
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)
Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease
-
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)
Evidence-based recommendations on pembrolizumab (Keytruda) for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in a
-
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) (TA662)
NICE is unable to make a recommendation on durvalumab (Imfinzi) in combination for untreated extensive-stage small-cell lung cancer in adults because AstraZenec
-
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)
Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab for untreated chronic lymphocytic leukaemia in adults
-
Liraglutide for managing overweight and obesity (TA664)
Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in
-
Upadacitinib for treating severe rheumatoid arthritis (TA665)
Evidence-based recommendations on upadacitinib (Rinvoq) for severe active rheumatoid arthritis in adults
-
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults
-
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura (TA667)
Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic
-
Guidance on the use of coronary artery stents (TA71)
Evidence-based recommendations on using coronary artery stents in adults
-
Siponimod for treating secondary progressive multiple sclerosis (TA656)
Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults
-
Carfilzomib for previously treated multiple myeloma (TA657)
Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults
-
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA658)
Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults
-
Drug-eluting stents for the treatment of coronary artery disease (TA152)
Evidence-based recommendations on using drug-eluting stents in adults
-
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)
Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in
-
Swallowable gastric balloon capsule for weight loss (IPG684)
Evidence-based recommendations on swallowable gastric balloon capsules for weight loss in adults. This involves swallowing a capsule containing a balloon that
-
Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis (IPG681)
Evidence-based recommendations on pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis in adults. This involves spraying the inside of
-
Balloon cryoablation for Barrett's oesophagus (IPG682)
Evidence-based recommendations on balloon cryoablation for Barrett’s oesophagus. This involves using a balloon filled with cold gas to destroy abnormal cells
-
Balloon cryoablation for squamous dysplasia of the oesophagus (IPG683)
Evidence-based recommendations on balloon cryoablation for squamous dysplasia of the oesophagus. This involves using a balloon filled with cold gas to destroy